PHOENIX PHARMACEUTICAL, INC. – Trademark Portfolio
Entity Type: 03
PHOENIX PHARMACEUTICAL, INC. holds 32 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 25 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include VETACRYL and PHENYLBUTE. The owner is based in ST. JOSEPH, MO.
P.O. BOX 7, FAIRLEIGH STATION
4621 EASTON ROAD
ST. JOSEPH, MO 64506
Showing of trademarks Trademarks
Trademark Classifications
PHOENIX PHARMACEUTICAL, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does PHOENIX PHARMACEUTICAL, INC. have?
PHOENIX PHARMACEUTICAL, INC. has 32 U.S. trademarks filed with the USPTO. Of these, 2 registered, 11 abandoned, 19 cancelled.
What trademark classes does PHOENIX PHARMACEUTICAL, INC. file in?
PHOENIX PHARMACEUTICAL, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are PHOENIX PHARMACEUTICAL, INC.'s most well-known trademarks?
PHOENIX PHARMACEUTICAL, INC.'s registered trademark portfolio includes well-known marks such as VETACRYL and PHENYLBUTE. These are among 2 currently registered trademarks in the portfolio.
What is PHOENIX PHARMACEUTICAL, INC.'s trademark registration success rate?
PHOENIX PHARMACEUTICAL, INC. has a 6% trademark registration rate, with 2 out of 32 resolved applications resulting in successful registration. Currently, 0 applications are pending review.